| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Other financing activities | -359 | -360 |
| Net cash provided by financing activities | 2,746 | 2,644 |
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | -139,439 | -12,417 |
| Cash and cash equivalents at beginning of period | 318,695 | - |
| Cash and cash equivalents at end of period | 179,256 | - |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)